Related Experiment Video
Updated: Nov 20, 2025
06:07
Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
2.8K
Targeting DNA methyltransferases in non-small-cell lung cancer
Minnatallah Al-Yozbaki1, Ibtissam Jabre2, Naeem H Syed1
1Canterbury Christ Church University, School of Human and Life Sciences, Life Sciences Industry Liaison Lab, Sandwich, UK.
Seminars in Cancer Biology
|January 24, 2021
Summary
Epigenetic therapies targeting DNA methyltransferases show promise for non-small cell lung cancer (NSCLC). Combining these with chemotherapy or immunotherapy, and exploring phytochemicals, offers new treatment avenues.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality globally, with limited survival improvements from current treatments.
- Epigenetic therapies, targeting DNA methyltransferases (DNMTs) and histone-modifying enzymes, are emerging strategies for NSCLC.
- Single-agent epigenetic therapy has shown limited efficacy in solid tumors.
Purpose of the Study:
- To review the role of DNA methyltransferases (DNMTs) in NSCLC.
- To discuss DNA methylation profiling in NSCLC.
- To provide an overview of current demethylating agents and future directions in epigenetic therapy for NSCLC.
Main Methods:
- Review of current literature on epigenetic mechanisms in NSCLC.
- Analysis of DNA methyltransferases (DNMTs) and their inhibitors.
- Discussion of clinical trials involving demethylating agents.
Main Results:
- Combination therapies involving DNMT inhibitors with chemotherapy and immunotherapy demonstrate significant promise.
- Dietary phytochemicals exhibit potential in inhibiting DNMTs and cancer stem cells, offering novel preventive and therapeutic strategies.
- Several demethylating agents are currently under investigation in clinical trials for NSCLC.
Conclusions:
- Epigenetic therapies, particularly combination approaches and those involving phytochemicals, represent a promising frontier for NSCLC treatment.
- Further research into DNMTs, DNA methylation, and novel demethylating agents is crucial for advancing NSCLC care.
